- Clinical Trials
Researchers at MD Anderson Cancer Center have conducted preclinical studies evaluating GPX-001 in combination with anti-PD1 checkpoint inhibitors, including pembrolizumab (Merck’s Keytruda®).
Positive and encouraging data indicate that GPX-001 is synergistic with immunotherapies.
In April 2019, we reported that our collaborators at MD Anderson presented positive preclinical data for the combination of TUSC2 with pembrolizumab, demonstrating that TUSC2 combined with checkpoint blockade was more effective than checkpoint blockade alone in increasing the survival of mice with human immune cells, that had metastatic lung cancer.
In November 2019, we reported that our collaborators at MD Anderson presented positive preclinical data for the combination of TUSC2, pembrolizumab and chemotherapy for the treatment of some of the most resistant metastatic lung cancers. This study found that the combination of TUSC2 increases the effectiveness of pembrolizumab and chemotherapy, and thus, may improve on first-line standard of care for lung cancer.
We are planning to open a Phase I/II clinical trial of GPX-001 combined with pembrolizumab.
To learn more about scientific evidence and studies supporting GPX-001 and the TUSC2 gene, please refer to our TUSC2 Bibliography page.
Keytruda® is a registered trademark of Merck.